Navigation Links
Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
Date:8/4/2008

EMERYVILLE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $2.1 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI's pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies CEO to Retire on December 31, 2008
2. Neurobiological Technologies Reports Third Quarter Financial Results
3. Neurobiological Technologies Sets Date for Third Quarter Financial Results
4. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Sets Date for Research and Development Day
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 ... für Molekulargenetik, erweitert seine Palette an anpassbaren SureSeq™ ... Custom FH Panels, das ein schnelles und kostengünstiges ... Das Panel bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single ... mit einem einzigen kleinen Panel und ermöglicht eine ...
(Date:12/8/2016)... ... 08, 2016 , ... Microbial genomics leader, uBiome, joins Google, ... of just six company finalists in the Health & Medicine category. Over 1,000 ... as finalists in this year’s awards include Google, SpaceX, Oculus, and SolarCity. Individuals ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016 ... augmentation remediation technologies and selected NewTechBio,s NT-MAX ... a microbial based beneficial bacteria, in conjunction with ... to correct deficiencies with National Pollutant Discharge Elimination ... 281-8H has experienced a steady history of elevated ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... that “in the setting of previously treated, advanced pancreatic cancer, liquid biopsies are ... optimal patient population and timing of blood sampling may improve the value of ...
Breaking Biology Technology:
(Date:12/8/2016)... ALAMEDA, Calif. , Dec. 8, 2016  Singulex, ... Single Molecule Counting technology, entered into a license and ... in serving science. The agreement provides Singulex access to ... Europe is used to diagnose ... the United States to aid in assessing ...
(Date:12/7/2016)... Israel , December 7, 2016 BioCatch ... the expansion of its patent portfolio, which grew to over 40 granted ... , , ... its recently filed patent entitled " System, Device, and Method ... technology that enables device makers to forego costly hardware components needed to ...
(Date:12/7/2016)... --  Veridium , a leader in biometrics-based authentication ... James Stickland . Stickland, a seasoned financial ... served in senior executive roles for HSBC, JPMorgan ... a pipeline of venture capital and accelerating innovation ... as managing director of U.K.-based fintech firm Red ...
Breaking Biology News(10 mins):